{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:36:56Z","timestamp":1794411416229,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K16628"],"award-info":[{"award-number":["20K16628"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08075"],"award-info":[{"award-number":["19K08075"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K07564"],"award-info":[{"award-number":["18K07564"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H02752"],"award-info":[{"award-number":["18H02752"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20dk0207025"],"award-info":[{"award-number":["JP20dk0207025"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18dk0307076"],"award-info":[{"award-number":["JP18dk0307076"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer's disease (AD) is a progressive disease, and the number of AD patients is increasing every year as the population ages. One of the pathophysiological mechanisms of AD is thought to be the effect of metabolomic abnormalities. There have been several studies of metabolomic abnormalities of AD, and new biomarkers are being investigated. Metabolomic studies have been attracting attention, and the aim of this study was to identify metabolomic biomarkers associated with AD and mild cognitive impairment (MCI). Of the 927 participants in the Nakayama Study conducted in Iyo City, Ehime Prefecture, 106 were selected for this study as Control (n\u2009=\u200940), MCI (n\u2009=\u200926), and AD (n\u2009=\u200940) groups, matched by age and sex. Metabolomic comparisons were made across the three groups. Then, correlations between metabolites and clinical symptoms were examined. The blood mRNA levels of the ornithine metabolic enzymes were also measured. Of the plasma metabolites, significant differences were found in ornithine, uracil, and lysine. Ornithine was significantly decreased in the AD group compared to the Control and MCI groups (Control vs. AD: 97.2 vs. 77.4; <jats:italic>P<\/jats:italic>\u2009=\u20090.01, MCI vs. AD: 92.5 vs. 77.4; <jats:italic>P<\/jats:italic>\u2009=\u20090.02). Uracil and lysine were also significantly decreased in the AD group compared to the Control group (uracil, Control vs. AD: 272 vs. 235; <jats:italic>P<\/jats:italic>\u2009=\u20090.04, lysine, Control vs. AD: 208 vs. 176; <jats:italic>P<\/jats:italic>\u2009=\u20090.03). In the total sample, the MMSE score was significantly correlated with lysine, ornithine, thymine, and uracil. The Barthel index score was significantly correlated with lysine. The instrumental activities of daily living (IADL) score were significantly correlated with lysine, betaine, creatine, and thymine. In the ornithine metabolism pathway, the spermine synthase mRNA level was significantly decreased in AD. Ornithine was decreased, and mRNA expressions related to its metabolism were changed in the AD group compared to the Control and MCI groups, suggesting an association between abnormal ornithine metabolism and AD. Increased betaine and decreased methionine may also have the potential to serve as markers of higher IADL in elderly persons. Plasma metabolites may be useful for predicting the progression of AD.<\/jats:p>","DOI":"10.1038\/s41598-022-19670-y","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T10:03:39Z","timestamp":1662631419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer\u2019s disease (from the Nakayama Study)"],"prefix":"10.1038","volume":"12","author":[{"given":"Tomoki","family":"Ozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Mawatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-3096","authenticated-orcid":false,"given":"Jun-ichi","family":"Iga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ichi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"19670_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/jnnp-2019-321913","volume":"91","author":"JT Yu","year":"2020","unstructured":"Yu, J. T. et al. Evidence-based prevention of Alzheimer\u2019s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J. Neurol. Neurosurg. Psychiatry 91, 1201\u20131209 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"19670_CR2","doi-asserted-by":"publisher","first-page":"700587","DOI":"10.3389\/fphar.2021.700587","volume":"12","author":"YY Wang","year":"2021","unstructured":"Wang, Y. Y. et al. Biomarkers for the clinical diagnosis of Alzheimer\u2019s disease: Metabolomics analysis of brain tissue and blood. Front. Pharmacol. 12, 700587 (2021).","journal-title":"Front. Pharmacol."},{"key":"19670_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11306-021-01828-w","volume":"17","author":"P Reveglia","year":"2021","unstructured":"Reveglia, P. et al. Challenges in LC-MS-based metabolomics for Alzheimer\u2019s disease early detection: targeted approaches versus untargeted approaches. Metabolomics 17, 78 (2021).","journal-title":"Metabolomics"},{"key":"19670_CR4","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1007\/s12035-020-02058-2","volume":"57","author":"S Ochi","year":"2020","unstructured":"Ochi, S. et al. Identifying blood transcriptome biomarkers of Alzheimer\u2019s disease using transgenic mice. Mol. Neurobiol. 57, 4941\u20134951 (2020).","journal-title":"Mol. Neurobiol."},{"key":"19670_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"19670_CR6","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4155\/bio-2018-0135","volume":"10","author":"MO Hurtado","year":"2018","unstructured":"Hurtado, M. O., Kohler, I. & de Lange, E. C. Next-generation biomarker discovery in Alzheimer\u2019s disease using metabolomics\u2014From animal to human studies. Bioanalysis 10, 1525\u20131546 (2018).","journal-title":"Bioanalysis"},{"key":"19670_CR7","doi-asserted-by":"publisher","first-page":"13764","DOI":"10.1038\/s41598-019-50205-0","volume":"9","author":"MG Fleszar","year":"2019","unstructured":"Fleszar, M. G. et al. Targeted metabolomic analysis of nitric oxide\/L-arginine pathway metabolites in dementia: Association with pathology, severity, and structural brain changes. Sci. Rep. 9, 13764 (2019).","journal-title":"Sci. Rep."},{"key":"19670_CR8","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1021\/ac900675k","volume":"81","author":"T Soga","year":"2009","unstructured":"Soga, T. et al. Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry. Anal. Chem. 81, 6165\u20136174 (2009).","journal-title":"Anal. Chem."},{"key":"19670_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1021\/pr034020m","volume":"2","author":"T Soga","year":"2003","unstructured":"Soga, T. et al. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J. Proteome Res. 2, 488\u2013494 (2003).","journal-title":"J. Proteome Res."},{"key":"19670_CR10","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1038\/tp.2014.19","volume":"4","author":"S Koike","year":"2014","unstructured":"Koike, S. et al. A snapshot of plasma metabolites in first-episode schizophrenia: A capillary electrophoresis time-of-flight mass spectrometry study. Transl. Psychiatry 4, e379 (2014).","journal-title":"Transl. Psychiatry"},{"key":"19670_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbacli.2016.03.008","volume":"5","author":"N Yoshimi","year":"2016","unstructured":"Yoshimi, N. et al. Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder. BBA Clin. 5, 151\u2013158 (2016).","journal-title":"BBA Clin."},{"key":"19670_CR12","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1038\/s41598-017-05121-6","volume":"7","author":"H Umehara","year":"2017","unstructured":"Umehara, H. et al. Altered KYN\/TRP, Gln\/Glu, and Met\/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder. Sci. Rep. 7, 4855 (2017).","journal-title":"Sci. Rep."},{"key":"19670_CR13","doi-asserted-by":"publisher","first-page":"e73814","DOI":"10.1371\/journal.pone.0073814","volume":"8","author":"H Kuwabara","year":"2013","unstructured":"Kuwabara, H. et al. Altered metabolites in the plasma of autism spectrum disorder: A capillary electrophoresis time-of-flight mass spectroscopy study. PLoS ONE 8, e73814 (2013).","journal-title":"PLoS ONE"},{"key":"19670_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3233\/JAD-210737","volume":"84","author":"S Sriwichaiin","year":"2021","unstructured":"Sriwichaiin, S., Chattipakorn, N. & Chattipakorn, S. C. Metabolomic alterations in the blood and brain in association with Alzheimer\u2019s disease: Evidence from in vivo to clinical studies. J. Alzheimers Dis. 84, 23\u201350 (2021).","journal-title":"J. Alzheimers Dis."},{"key":"19670_CR15","doi-asserted-by":"publisher","first-page":"e0119452","DOI":"10.1371\/journal.pone.0119452","volume":"10","author":"SF Graham","year":"2015","unstructured":"Graham, S. F. et al. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer\u2019s disease. PLoS ONE 10, e0119452 (2015).","journal-title":"PLoS ONE"},{"key":"19670_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12199-020-00903-3","volume":"25","author":"T Ninomiya","year":"2020","unstructured":"Ninomiya, T. et al. Study design and baseline characteristics of a population-based prospective cohort study of dementia in Japan: the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). Environ. Health Prev. Med. 25, 64 (2020).","journal-title":"Environ. Health Prev. Med."},{"key":"19670_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12864-021-07612-3","volume":"22","author":"Y Yoshino","year":"2021","unstructured":"Yoshino, Y. et al. Effects of AGXT2 variants on blood pressure and blood sugar among 750 older Japanese subjects recruited by the complete enumeration survey method. BMC Genomics 22, 287 (2021).","journal-title":"BMC Genomics"},{"key":"19670_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"19670_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2015.03.004","volume":"66\u201367","author":"SY Watanabe","year":"2015","unstructured":"Watanabe, S. Y. et al. Biological tests for major depressive disorder that involve leukocyte gene expression assays. J. Psychiatr Res. 66\u201367, 1\u20136 (2015).","journal-title":"J. Psychiatr Res."},{"key":"19670_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/hup.2381","volume":"29","author":"S Watanabe","year":"2014","unstructured":"Watanabe, S. et al. Microarray analysis of global gene expression in leukocytes following lithium treatment. Hum. Psychopharmacol. 29, 190\u2013198 (2014).","journal-title":"Hum. Psychopharmacol."},{"key":"19670_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jchromb.2018.05.031","volume":"1091","author":"Y Muguruma","year":"2018","unstructured":"Muguruma, Y., Tsutsui, H., Noda, T., Akatsu, H. & Inoue, K. Widely targeted metabolomics of Alzheimer\u2019s disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1091, 53\u201366 (2018).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"19670_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jalz.2017.11.012","volume":"14","author":"SJ van der Lee","year":"2018","unstructured":"van der Lee, S. J. et al. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimers Dement. 14, 707\u2013722 (2018).","journal-title":"Alzheimers Dement."},{"key":"19670_CR23","doi-asserted-by":"publisher","first-page":"582998","DOI":"10.3389\/fimmu.2020.582998","volume":"11","author":"C Ma","year":"2020","unstructured":"Ma, C. et al. Arginase 1 insufficiency precipitates amyloid-beta deposition and hastens behavioral impairment in a mouse model of amyloidosis. Front. Immunol. 11, 582998 (2020).","journal-title":"Front. Immunol."},{"key":"19670_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10545-010-9088-4","volume":"34","author":"PM Ueland","year":"2011","unstructured":"Ueland, P. M. Choline and betaine in health and disease. J. Inherit. Metab. Dis. 34, 3\u201315 (2011).","journal-title":"J. Inherit. Metab. Dis."},{"key":"19670_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3233\/JAD-200972","volume":"79","author":"D Ibi","year":"2021","unstructured":"Ibi, D. et al. Preventive effects of continuous betaine intake on cognitive impairment and aberrant gene expression in hippocampus of 3xTg mouse model of Alzheimer\u2019s disease. J. Alzheimers Dis. 79, 639\u2013652 (2021).","journal-title":"J. Alzheimers Dis."},{"key":"19670_CR26","doi-asserted-by":"publisher","first-page":"e22090","DOI":"10.1002\/jcla.22090","volume":"31","author":"J Sun","year":"2017","unstructured":"Sun, J., Wen, S., Zhou, J. & Ding, S. Association between malnutrition and hyperhomocysteine in Alzheimer\u2019s disease patients and diet intervention of betaine. J. Clin. Lab. Anal. 31, e22090 (2017).","journal-title":"J. Clin. Lab. Anal."},{"key":"19670_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/JAD-191226","volume":"74","author":"O Jaaskelainen","year":"2020","unstructured":"Jaaskelainen, O. et al. Metabolic profiles help discriminate mild cognitive impairment from dementia stage in Alzheimer\u2019s disease. J. Alzheimers Dis. 74, 277\u2013286 (2020).","journal-title":"J. Alzheimers Dis."},{"key":"19670_CR28","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3233\/JAD-200305","volume":"78","author":"A Yilmaz","year":"2020","unstructured":"Yilmaz, A. et al. A Community-based study identifying metabolic biomarkers of mild cognitive impairment and Alzheimer\u2019s disease using artificial intelligence and machine learning. J. Alzheimers Dis. 78, 1381\u20131392 (2020).","journal-title":"J. Alzheimers Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19670-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T11:23:59Z","timestamp":1708082639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19670-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19670"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19670-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"11 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15205"}}